Oblato, Inc., has acquired all rights from OMRF to OKN-007, an investigational drug for the treatment of a deadly form of brain cancer.
OMRF has entered a license agreement with Shanghai RAAS Blood Products for development of novel hemophilia treatment.
OBI’s new software system, Bio-Linked, will be used to match willing blood donors with researchers at OMRF to build a volunteer group for StopRA.
Visiting attendees represented some of the top names in in the industry.
The first project will focus on a new way to predict disease flares in lupus.